---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-25-035535"
form_type: "8-K"
ticker: "CERO"
cik: "0001870404"
company_name: "CERO THERAPEUTICS HOLDINGS, INC."
filed_at: "2025-04-25T23:59:59+00:00"
generated_at: "2026-05-23T06:04:58.315171+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "medium"
source: SEC EDGAR
---

# CERo files Series D Preferred Stock designation; regains Nasdaq bid price compliance

## Summary
- Filed Certificate of Designations for Series D convertible preferred stock effective April 22, 2025, part of previously reported securities purchase agreement.
- April 24 closing price was $1.11, ending 26 consecutive trading days below $1.00.
- No longer imminent risk of failing Nasdaq's minimum bid price requirement, though future risk remains.
- Corporate presentation dated April 2025 furnished; exhibit contains no new specific operational or financial data.

## SEC filing metadata
- accession: 0001213900-25-035535
- form_type: 8-K
- ticker: CERO
- cik: 0001870404
- company_name: CERO THERAPEUTICS HOLDINGS, INC.
- filed_at: 2025-04-25T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: medium
- sec_items: 5.03, 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1870404/000121390025035535/0001213900-25-035535-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1870404/000121390025035535/ea0239321-8k_cero.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-25-035535
- JSON: https://secwatch.observer/filing/0001213900-25-035535.json
- Plain text: https://secwatch.observer/filing/0001213900-25-035535.txt

## Key facts
- Governance Changes
  CERO THERAPEUTICS HOLDINGS, INC.: Filed Certificate of Designations for Series D convertible preferred stock (effective 2025-04-22).
  - Change: charter amendment
  - Effective: 2025-04-22
  source text: On April 22, 2025, CERo Therapeutics Holdings, Inc. (the “Company”) filed the Certificate of Designations of Rights and Preferences of the Series D Preferred Stock (the “Certificate of Designations”) for the purpose of designating and establishing the Company’s Series D convertible preferred stock, par value $0.0001 per share (the “Series D Preferred Stock”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1870404/000121390025035535/0001213900-25-035535-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.